Diffuse Large B-cell Lymphoma
📧 Sign up to get email alerts when something new happens for Diffuse Large B-cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-03-24Clinical Trial Update: Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma [Phase 3]
Phase 3 study evaluating loncastuximab tesirine with rituximab versus immunochemotherapy in relapsed or refractory diffuse large B-cell lymp…
-
CLINICAL_TRIALS trial_result · 2026-03-24Clinical Trial Update: Maintenance Therapy of Chidamide in Patients With HBV Positive Diffuse Large B-cell Lymphoma [Phase 2]
Phase 2 trial evaluating maintenance therapy with chidamide in HBV-positive Diffuse Large B-cell Lymphoma has completed. The study assessed …
-
CLINICAL_TRIALS research · 2026-03-24Clinical Trial Update: Enhancing CAR-T Cell Therapy Efficacy in B-cell Lymphoma Via Chidamide and PD-1 Inhibitor Combination. [Phase 2]
A Phase 2 clinical trial is evaluating whether combining chidamide and a PD-1 inhibitor can improve the efficacy of CAR-T cell therapy in re…
-
CLINICAL_TRIALS research · 2026-03-24Clinical Trial Update: Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype [Phase 2]
Phase 2 study evaluating nemtabrutinib combined with pembrolizumab for Richter transformation and Diffuse Large B-Cell Lymphoma in patients …
-
CLINICAL_TRIALS research · 2026-03-24Clinical Trial Update: A Study of Ultra-fraction Radiotherapy Bridging CART in R/R DLBCL [NA]
Clinical trial update for a study evaluating ultra-fraction radiotherapy as bridging therapy before CAR-T in relapsed/refractory diffuse lar…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-03-23Clinical Trial Update: Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma [Phase 1]
Phase 1 clinical trial evaluating Rituximab plus Bendamustine and ibrutinib (PCI-32765) in relapsed DLBCL, mantle cell lymphoma, and various…
-
CLINICAL_TRIALS research · 2026-03-20Clinical Trial Update: A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies [Phase 1]
Phase 1 study evaluating NX-2127 in adults with relapsed or refractory B-cell malignancies; currently recruiting.
-
CLINICAL_TRIALS trial_result · 2026-03-20Clinical Trial Update: ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma [Phase 1, Phase 2]
A Phase 1/2 study evaluating ALX148 in combination with Rituximab and Lenalidomide for various B-cell non-Hodgkin lymphomas, with the trial …
-
CLINICAL_TRIALS research · 2026-03-20Clinical Trial Update: NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma [Phase 1]
This clinical trial update describes a Phase 1 study of NKTR-255 in combination with CAR-T cell therapy for relapsed or refractory large B-c…
-
CLINICAL_TRIALS trial_result · 2026-03-20Clinical Trial Update: A Study of LY4152199 in Participants With Previously Treated B-cell Cancers (BAF_FRontier-1 ) [Phase 1]
A Phase 1 study of LY4152199 in previously treated B-cell cancers is listed, with the trial currently NOT_YET_RECRUITING.
-
FDA approval · 2026-03-18FDA Approved: POLIVY — Supplemental Application (Genentech, Inc.)
The FDA approved a supplemental application for POLIVY (polatuzumab vedotin) from Genentech, expanding its labeled use.
-
CLINICAL_TRIALS trial_result · 2026-03-18Clinical Trial Update: Efficacy and Safety of Glofitamab Combined With GemOxin the Treatment of Refractory Diffuse Large B-Cell Lymphoma [Phase 2]
This clinical trial update reports on the efficacy and safety of combining glofitamab with GemOx (gemcitabine plus oxaliplatin) in patients …
-
CLINICAL_TRIALS research · 2026-03-18Clinical Trial Update: Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom [Phase 2]
Phase 2 clinical trial update for CLR-131 in select B-cell malignancies, with expansion into Waldenström macroglobulinemia. The study status…
-
CLINICAL_TRIALS research · 2026-03-18Clinical Trial Update: CAR-T Followed by Bispecific Antibodies [Phase 2]
Phase 2 clinical trial evaluating sequencing of CAR-T therapy followed by bispecific antibodies in diffuse large B-cell lymphoma; currently …
-
CLINICAL_TRIALS research · 2026-03-18Clinical Trial Update: A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma [Phase 1]
AstraZeneca reports a Phase 1 clinical trial of AZD0486 in B-cell non-Hodgkin lymphomas, including diffuse large B-cell lymphoma, high-grade…
-
CLINICAL_TRIALS research · 2026-03-18Clinical Trial Update: Radiation, Oral Vancomycin, and CAR-T for B-Cell Lymphomas [Phase 1]
Phase 1 clinical trial update evaluating radiation therapy, oral vancomycin, and CAR-T cell therapy for large B-cell/Non-Hodgkin lymphoma, c…
-
CLINICAL_TRIALS trial_result · 2026-03-17Clinical Trial Update: Treatment of Patients With Diffuse Large B Cell Lymphoma Who Are Not Suitable for Anthracycline Containing Chemotherapy [Phase 2]
Phase 2 clinical trial evaluating treatment for patients with diffuse large B-cell lymphoma who are not suitable for anthracycline-containin…
-
CLINICAL_TRIALS trial_result · 2026-03-17Clinical Trial Update: A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML [Phase 1]
Phase 1 trial update for voruciclib alone or with venetoclax in various B-cell malignancies and acute myeloid leukemia; the study has been t…
-
CLINICAL_TRIALS research · 2026-03-17Clinical Trial Update: A Study to Evaluate MTM-H-001 Injection in Adult Participants With Relapsed or Refractory B-cell Malignancies [NA]
This clinical trial update describes an evaluation of MTM-H-001 injection in adults with relapsed or refractory B-cell lymphomas, with the s…
-
CLINICAL_TRIALS trial_result · 2026-03-16Clinical Trial Update: Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy [Phase 2]
Phase 2 clinical trial evaluating a CD3xCD20 bispecific antibody for relapse/refractory B-cell non-Hodgkin lymphomas after CAR-T therapy has…
-
CLINICAL_TRIALS trial_result · 2026-03-16Clinical Trial Update: Real-World Effectiveness and Safety of Glofitamab in Primary Refractory and Early Relapsed Diffuse Large B-Cell Lymphoma
This clinical trial update reports real-world effectiveness and safety of glofitamab in patients with primary refractory and early relapsed …
-
CLINICAL_TRIALS research · 2026-03-16Clinical Trial Update: CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma [Phase 1]
A Phase 1 clinical trial evaluating CD79b-19 CAR T cells for relapsed or refractory non-Hodgkin lymphoma, including several subtypes, is cur…
-
CLINICAL_TRIALS research · 2026-03-16Clinical Trial Update: Study of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients [Phase 1, Phase 2]
This clinical trial update describes a Phase 1/2 study of TC011 for relapsed/refractory large B-cell non-Hodgkin lymphoma, assessing safety …
-
CLINICAL_TRIALS research · 2026-03-13Clinical Trial Update: Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T [Phase 2]
Phase 2 clinical trial evaluating Odronextamab for relapsed or refractory large B-cell lymphomas before CAR-T therapy; the study is currentl…
-
CLINICAL_TRIALS research · 2026-03-13Clinical Trial Update: Neurocognitive Assessment in Adults Undergoing CD19 Targeted CAR-T Cell Therapy
This clinical trial update describes neurocognitive assessment in adults undergoing CD19-targeted CAR-T cell therapy for certain B-cell lymp…